Delphi focuses on two key healthcare sectors: medical devices and biotechnology. We've recruited a team of partners with deep expertise in these areas. Our diversification provides a valuable mix of opportunities. And as industry sectors blur - as biology, chemistry, and genomic advances impact the development and delivery of new treatments; as more companies begin to bundle information technology with diagnostic products; and as complex disease processes get deciphered - Delphi's understanding of the different healthcare sectors will be essential to our continued success.
“We invest in venture capital firms that provide specific industry expertise and have a demonstrated track record of success. Delphi Ventures has had a long-standing commitment to healthcare highlighted by outstanding medical device and biotechnology investments. Delphi is second to none.”
Jim Lim, General Partner, Greenspring Associates
Our medical device companies target multi-hundred million to multi-billion dollar markets. These markets include cardiovascular medicine, orthopedics, gynecology, minimally invasive surgery, urology, neurovascular medicine and next-generation diagnostics. To date, approximately one-half of all our private equity investments have been in the medical device sector. Nearly half of the medical device companies that we have financed are now public companies or have been acquired.
We focus on the strength of a company's patent position, as well as the quality and compelling nature of its clinical results. Tapping Delphi's understanding of markets, we carefully analyze a company for its ability to meet FDA approval and reimbursement requirements. We understand first-hand that without a clear path for obtaining regulatory approval and reimbursement, market success is out of reach. Our companies are led by senior managers, including CEOs, engineers and physicians with proven industry track records.
Delphi invests in biotechnology companies that have broad discovery platforms that have generated multiple product possibilities. The biotechnology companies in our portfolio are at the crossroads of biology, chemistry, and technology and are focused on developing drugs that serve large patient communities with on-going and unmet medical needs. We have invested in more than 45 biotechnology companies. More than half have gone public or have been acquired by major pharmaceutical companies.
Delphi typically invests after a company has either generated early human clinical data or completed preclinical efficacy and toxicity studies. We carefully analyze feasibility of clinical trials, regulatory hurdles, and commercial competitiveness by tapping into our extensive network and our understanding of developing markets. As with all our venture investments, we only invest in companies with exceptional management and clinical development teams.